Hims & Hers stock outlook: Downside risk rises on earnings miss and bearish momentum

Traders Union
All News
Stocks
Hims & Hers drops 16.59% today

Highlights

Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, a 49% year-over-year increase but below analyst expectations, with a net loss of $33 million from higher operating expenses.
The company lowered its full-year revenue and adjusted EBITDA forecasts due to margin pressure and faces rising regulatory risk after a new FTC complaint regarding sensitive health data.
Shares of Hims & Hers fell 16.59% to $19.13 on strong selling momentum, with technicals indicating a 77% probability of continued downside within a $15.3 to $22.96 range.

Profitability outlook dims as margin pressure and regulatory threats mount

Hims & Hers Health Inc reported third-quarter 2026 revenue of $890.4 million, a 49% increase year-over-year but below analyst estimates, along with a net loss of $33 million due to higher operating costs from expansion initiatives, according to Yahoo Finance. The company also revised its full-year revenue and adjusted EBITDA guidance downward, citing margin pressure, which raises concerns about earnings potential and future profitability. Regulatory uncertainty also escalated after the US Federal Trade Commission and state plaintiffs filed an amended complaint on November 10, 2026, alleging improper sharing of sensitive consumer health data, as reported by Mlex. In parallel, Hims & Hers has announced upcoming plans to launch its Peptides+ product line by late November, with future additions dependent on regulatory approval, as noted by Gurufocus.

Bearish momentum dominates as resistance and oversold signals emerge

HIMS is trading below the MA-20, MA-50, and MA-200 levels, with a non-zero gap down of $0.82 and price trading near the session's low. The Ichimoku Kijun at $22.32 marks immediate resistance, while key support is seen at $15.3. Momentum signals are firmly bearish; both MACD and ADX register Sell, and Bull/Bear Power stands at -1.55, highlighting seller dominance intraday. RSI sits in oversold territory, but Stochastic RSI and CCI remain neutral, showing selling exhaustion on the RSI but no overshoot on other oscillators. Awesome Oscillator is neutral and does not offer additional trend confirmation.

Downside risk prevails as volatility defines near-term price corridor

Looking ahead over the next several sessions, the expected price band for HIMS is between $15.3 and $22.96, reflecting heightened volatility. The probability of further downside remains elevated at 77%, with only a 23% chance of an upward reversal. Baseline expectation is consolidation within this corridor. If price breaks above the $22.32 Ichimoku Kijun resistance, upside momentum could emerge, but a move below $15.3 would open the way to extended weakness and additional declines.

Viktoras Karapetjanc, analyst at Traders Union, sees HIMS pressured by both weaker fundamentals and regulatory headwinds. He believes the sharp drop in earnings and lowered guidance have eroded sentiment, while legal uncertainty compounds investor caution. Despite the company's growth moves, margin pressure and downside momentum remain dominant. "If HIMS can hold above $15.3 and resolve regulatory risks, I expect sentiment to recover in subsequent quarters."

Previously it was reported that Hims & Hers faced persistent selling pressure after disappointing Q3 earnings and reduced guidance, highlighting ongoing margin and profitability challenges. The latest developments reinforce this negative outlook, with attention now focused on the $15.3 support level as a critical threshold for short-term downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.